Study details
Enrolling now
E7 TCR-T Cell Immunotherapy for HPV Associated Cancers
Christian Hinrichs
NCT IDNCT05686226ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
20
Study length
about 3.8 years
Ages
18+
Locations
3 sites in MD, NJ
What this study is about
This trial is testing a new immunotherapy called E7 TCR-T cells to treat advanced cancers caused by the human papillomavirus (HPV). Participants will receive this treatment along with other medications, and their response to treatment will be monitored.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive E7 TCR-T cells
- 2.Take Aldesleukin
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
aldesleukin
Endpoints
Primary: Tumor response
Secondary: Adverse Events
Body systems
Oncology